A long-acting subcutaneous antipsychotic (LASCA) suspension that combines risperidone with a novel copolymer substantially reduces both risk for relapse and time to impending relapse for patients with schizophrenia, new research suggests.
1 Like
A drug is more likely to work if you are forced to take it.